As the number of Americans with Alzheimer’s disease continues to soar, the Global Alzheimer’s Platform (GAP) Foundation is establishing a new model to speed Alzheimer’s clinical trials and increase participation in research. To achieved its goal, the foundation is launching various measures to slash trial cycle times by up…
Billionaire Bill Gates is joining efforts to develop new treatments for Alzheimer’s disease. Gates made the announcement in a recent blog post in which he outlined five areas where more research focus is needed. As a first step toward his commitment, Gates is investing $50 million in the…
Cognition Therapeutics’ lead drug candidate for mild-to-moderate Alzheimer’s disease (AD), CT1812, was shown to be well-tolerated and to lower brain levels of proteins involved in the disease, the company reports. These results, part of a Phase 1b/2a clinical trial, were given in an oral presentation at the recent 10th…
A novel strategy using healthy plasma infusions led to promising results in patients with mild to moderate Alzheimer’s disease, Alkahest recently announced. Stanford Medicine presented clinical data of its PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (NCT02256306) Nov. 4 at the 10th Clinical Trials on Alzheimer’s Disease conference in…
Aducanamab helps reduce amyloid plaques in Alzheimer’s patients who receive a gradually increasing dose of the therapy, its developer, Biogen, reports, citing results from the long-term extension of its ongoing Phase 1b study (NCT01677572). The potential treatment, also known as BIIB037, is a human monoclonal antibody derived from…
Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data presented during the recent 10th Clinical Trials on Alzheimer’s…
Acadia Pharmaceuticals reports that pimavanserin was particularly effective in treating psychosis in Alzheimer’s disease patients who had severe psychotic symptoms, without triggering a deterioration in their cognition. The information, which stems from additional analyses of data gathered in a Phase 2 trial of pimavanserin in Alzheimer’s patients, was…
Otsuka Pharmaceutical announced that it and Lundbeck will launch a third Phase 3 clinical trial of brexpiprazole to possibly treat agitation in patients with dementia linked to probable Alzheimer’s disease. Brexpiprazole, under the brand name Rexulti, was approved in the United States to treat people with schizophrenia and as an adjunct treatment…
Researchers have found that long-term use of opioids is not associated with an increased risk of Alzheimer’s disease (AD). The research was part of Finland’s nationwide MEDALZ study, and the findings were published in the journal Pain Medicine under the title “Is Alzheimer’s Disease Associated with Previous…
Researchers may have discovered the reason certain investigational therapies failed in Alzheimer’s disease clinical trials — a finding that could lead to new trials with a greater chance of success, according to a study published in the journal Cell Reports. A class of drugs, intended to block an enzyme…
Get regular updates to your inbox.